These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 20548159)

  • 21. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography.
    Leboulleux S; Dromain C; Bonniaud G; Aupérin A; Caillou B; Lumbroso J; Sigal R; Baudin E; Schlumberger M
    J Clin Endocrinol Metab; 2006 Mar; 91(3):920-5. PubMed ID: 16368753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL; Fischman AJ
    Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
    J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
    Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck.
    Ng SH; Yen TC; Chang JT; Chan SC; Ko SF; Wang HM; Lee LY; Kang CJ; Wong AM; Liao CT
    J Clin Oncol; 2006 Sep; 24(27):4371-6. PubMed ID: 16983105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of intrathoracic lesions detected by 18F-fluorodeoxyglucose positron emission tomography in the management of patients with head and neck cancer.
    Roh JL; Ryu CH; Kim JS; Lee JS; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Sep; 43(8):757-63. PubMed ID: 17112773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Percutaneous endoscopic gastrostomy site metastases in head and neck cancer: use of FDG PET-CT.
    Purandare NC; Rangarajan V; Sharma AR; Shah S; Singh N; Arora A; Pathak S; Deshpande M
    Diagn Interv Radiol; 2008 Jun; 14(2):88-93. PubMed ID: 18553282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Combined FDG PET/CT imaging for restaging of colorectal cancer patients: impact of image fusion on staging accuracy].
    Strunk H; Bucerius J; Jaeger U; Joe A; Flacke S; Reinhardt M; Hortling N; Palmedo H
    Rofo; 2005 Sep; 177(9):1235-41. PubMed ID: 16123869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer.
    Yen TC; Ng KK; Ma SY; Chou HH; Tsai CS; Hsueh S; Chang TC; Hong JH; See LC; Lin WJ; Chen JT; Huang KG; Lui KW; Lai CH
    J Clin Oncol; 2003 Oct; 21(19):3651-8. PubMed ID: 14512397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
    Park JW; Jo MK; Lee HM
    BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
    Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H
    Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of 18F-FDG PET/CT, CT and X-rays in detecting primary stage III A lung cancer and the incidence of extra thoracic metastases.
    Sharma R; Tripathi M; D'Souza M; Jaimini A; Saw SK; Singh D; Mishra A; Mondal A
    Hell J Nucl Med; 2009; 12(1):22-5. PubMed ID: 19330177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up.
    Yapar Z; Kibar M; Yapar AF; Paydas S; Reyhan M; Kara O; Buyukdereli G; Aydin M; Kelle AP; Unal I; Disel U; Yavuz S; Sahin B; Erkisi M
    Nucl Med Commun; 2010 Jan; 31(1):59-66. PubMed ID: 19952921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
    Metser U; You J; McSweeney S; Freeman M; Hendler A
    AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: a prospective multicenter trial.
    Senft A; de Bree R; Hoekstra OS; Kuik DJ; Golding RP; Oyen WJ; Pruim J; van den Hoogen FJ; Roodenburg JL; Leemans CR
    Radiother Oncol; 2008 May; 87(2):221-9. PubMed ID: 18410977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer.
    Lardinois D; Weder W; Roudas M; von Schulthess GK; Tutic M; Moch H; Stahel RA; Steinert HC
    J Clin Oncol; 2005 Oct; 23(28):6846-53. PubMed ID: 16192576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PET and PET-CT. State of the art and future prospects.
    Fanti S; Franchi R; Battista G; Monetti N; Canini R
    Radiol Med; 2005; 110(1-2):1-15. PubMed ID: 16163136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.